SCHEMBL709619

SCHEMBL709619

FC(F)(F)c1ccc(-n2ccnc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
MAPT P10636 2/20 0.58
ENPP2 Q13822 1/20 0.58
MKNK1 Q9BUB5 1/20 0.58
MKNK2 Q9HBH9 1/20 0.58
NOTUM Q6P988 1/20 0.58
CYP3A4 P08684 5/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50
PMP22 Q01453 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
BAZ2B Q9UIF8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3994163 0.85 EPHX2 (0.61) LMNAMAPTCYP3A4KMT2ACYP1A2
SCHEMBL20379023 0.84 LMNA (0.62) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL2532397 0.83 LMNA (0.78) LMNAMAPTENPP2MKNK1MKNK2
Hydrochloric Acid SCHEMBL28701756 0.81 LMNA (0.75) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL270275 0.81 MAPT (0.58) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL18290496 0.81 CYP3A4 (0.47) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL1882019 0.81 CYP3A4 (0.47) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL4883098 0.80 CD38 (0.53) LMNAMAPTCYP3A4KMT2ACYP1A2
Hydrochloric Acid SCHEMBL17583800 0.79 CYP3A4 (0.46) LMNAMAPTENPP2MKNK1MKNK2
SCHEMBL3250899 0.79 CYP3A4 (0.71) LMNAMAPTENPP2MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US claimed
EP-4712965-A2 BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD Springworks Therapeutics, Inc. (US) 2026-03-25 EP disclosed
CN-119627204-A Solid electrolyte and precursor thereof 香港科技大学 2025-03-14 CN disclosed
US-20240383891-A1 BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD CISTIM LEUVEN VZW (BE) 2024-11-21 US disclosed
WO-2024238738-A2 BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed
EP-2467398-B1 TRPC4 INHIBITORS AND USES THEREOF POSEIDA THERAPEUTICS INC (US) 2019-10-09 EP disclosed
CN-108349904-A PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF 米托布里奇公司 2018-07-31 CN disclosed
US-9018394-B2 Method for producing aromatic compound having ring structure that includes nitrogen atom or oxygen atom NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2015-04-28 US disclosed
US-20130338371-A1 METHOD FOR PRODUCING AROMATIC COMPOUND HAVING RING STRUCTURE THAT INCLUDES NITROGEN ATOM OR OXYGEN ATOM NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2013-12-19 US disclosed
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
EP-1509502-A1 METHOD OF FORMING A CARBON-CARBON OR CARBON-HETEROATOM LINKAGE RHODIA CHIMIE (FR) 2005-03-02 EP disclosed
WO-2005005382-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2005-01-20 WO disclosed
WO-2003101966-A1 METHOD OF FORMING A CARBON-CARBON OR CARBON-HETEROATOM LINKAGE RHODIA CHIMIE (FR) 2003-12-11 WO disclosed
EP-1337516-A1 PROCESS FOR MANUFACTURE OF IMIDAZOLES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-08-27 EP disclosed
WO-2002040454-A1 PROCESS FOR MANUFACTURE OF IMIDAZOLES THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) 2002-05-23 WO disclosed
US-6177575-B1 CONTACTING IN THE LIQUID PHASE AMMONIUM CARBONATE OR AMMONIUM BICARBONATE, A GLYOXAL, AN ALDEHYDE, AND OPTIONALLY AN AMINE E. I. DU PONT DE NEMOURS AND COMPANY 2001-01-23 US disclosed
CN-1218801-A Tri-substituted imidazoles, and process of their preparation and using the same and having their pharmic composition SMITHKLINE BEECHAM CORP (US) 1999-06-09 CN disclosed
CN-1129447-A Trisubstituted imidazoles having multiple therapeutic effects SMITHKLINE BEECHAM CORP (US) 1996-08-21 CN disclosed
EP-0003560-B1 IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS THE WELLCOME FOUNDATION LIMITED (GB) 1984-05-02 EP disclosed
US-4431815-A CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS BURROUGHS WELLCOME CO. (US) 1984-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383891-A1 BENZIMIDAZOLE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD2, TEAD1 LMNA 1774/4885MAPT 2668/4885ENPP2 2881/4885
US-20130338371-A1 METHOD FOR PRODUCING AROMATIC COMPOUND HAVING RING STRUCTURE THAT INCLUDES NITROGEN ATOM OR OXYGEN ATOM TH, AOC3, NOX3 LMNA 2611/4885MAPT 3111/4885ENPP2 4032/4885
US-20120148604-A1 TRP INHIBITORS AND USES THEREOF TRPC4, TRPC1, TRPC3 LMNA 4221/4885MAPT 2884/4885ENPP2 733/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 LMNA 4301/4885MAPT 1815/4885ENPP2 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.